Clinical mass spectrometry in neuroscience. Proteomics and peptidomics.
Review article, 2003
In this review we discuss the merits and drawbacks with the use of proteomic and peptidomic strategies for identification of proteins and peptides in their multidimensional interactions in complex biological processes. The progress in proteomics and peptidomics during the last years offer us new challenges to study changes in the protein and peptide synthesis. These strategies also offer new tools to follow post-translational modifications and other disturbed chemical processes that may be indicative of pathophysiological alteration(s). Furthermore these techniques can contribute to improvements in the diagnosis and therapy of neurodegenerative diseases, such as Alzheimer's disease, and psychiatric diseases, as depression and post traumatic stress disorders. We also consider different practical aspects of the applications of mass spectrometry in clinical neuroscience, illustrated by example from our laboratories. The new proteomic and peptidomic strategies will further enable the progress for clinical neuroscience research.
metabolism
metabolism
metabolism
Arteriosclerosis
diagnosis
methods
metabolism
diagnosis
analysis
Proteomics
Proteins
chemistry
diagnosis
Mass Spectrometry
Dementia
Central Nervous System Diseases
methods
metabolism
Brain Neoplasms
Humans
Cerebrospinal Fluid
Peptides
diagnosis
analysis
Neurosciences
Author
Pia Davidsson
University of Gothenburg
Ann Brinkmalm-Westman
University of Gothenburg
G Karlsson
University of Gothenburg
R Persson
University of Gothenburg
Maria Lindbjer
University of Gothenburg
Maja Puchades
University of Gothenburg
S Folkesson
University of Gothenburg
Linda Paulson
University of Gothenburg
Annika Dahl
University of Gothenburg
Lars Rymo
University of Gothenburg
J Silberring
Rolf Ekman
University of Gothenburg
Kaj Blennow
University of Gothenburg
Cellular and Molecular Biology
0145-5680 (ISSN) 1165-158X (eISSN)
Vol. 49 5 681-8Subject Categories
Physiology
PubMed
14528905